Synthesis and Evaluation of α-Halogenated
ABSTRACT Three α-halogenated analogues of 3-(acetylhydroxyamino)propyl phosphonic acid (FR900098) have been synthesized from diethyl but-3-enylphosphonate using a previously described method for the α-halogenation of alkylphosphonates. These analogues were evaluated for antimalarial potential in vitro against Plasmodium falciparum and in vivo in the P. berghei mouse model. All three analogues showed higher in vitro and/or in vivo potency than the reference compounds.
Intr oduction
Despite huge efforts already taken, malaria still poses a major threat to public health and the economy of affected countries. 1 With resistance emerging to virtually all available therapeutics, new antimalarials directed against new targets are highly awaited. 2 In this respect, the non-mevalonate pathway for isoprenoid biosynthesis (also known as the MEP pathway) and considered essential in all malariacausing Plasmodium species constitutes a promising target.
this study
This pathway is unrelated to the classical mevalonate pathway (HMG-CoA reductase pathway) present in all higher eukaryotes and starts with the condensation of pyruvate and glyceraldehyde-3-phosphate to 1-deoxy-D-xylulose-5-phosphate (DOXP).
Thus far, the second enzyme DOXP reductoisomerase (DXR), which catalyses the conversion of DOXP into 2-C-methyl-D-erythritol-3-phosphate (MEP), is the best investigated target in the search for new antibiotics, antimalarials and herbicides tackling the non-mevalonate pathway (Chart 1).
Chart 1
Fosmidomycin (1) and its acetyl congener 2 (FR900098) 4 , structurally simple antibiotics isolated from 7, 12 Consonantly with the hypothesis that increasing the acidity of the phosphonate moiety might confer improved activity, fosfoxacin (4), the phosphate analogue of fosmidomycin, and its acetyl congener were found to be more potent inhibitors of Synechocystis sp. PCC6803 DXR than fosmidomycin. 7 Since the metabolic liability of the phosphate precludes its in vivo use as a DXR inhibitor, we decided to investigate if the phosphonate group of fosmidomycin could be manipulated to more accurately mimic the electronic nature of the phosphate moiety present in fosfoxacin and the DOXP substrate.
Nieschalk et al. 13 showed that a monofluoromethylenephosphonate moiety can be a better phosphate mimic than the more popular difluoromethylenephosphonates often used for this goal, as the former one has a second pKa essentially equal to that of an organophosphate, whereas a difluoromethylenephosphonate is more acidic. Hence, we undertook the synthesis of α-halogenated fosmidomycin analogues 5a and b in which the required electron withdrawing effect comes from the halogen instead of the sterically more demanding aromatic group as in 3, possibly resulting in a better fit into the active pocket of DXR.
As stated above, modification of the N-formyl or N-acetyl retrohydroxamate in these structures usually results in a total loss of inhibitory activity. 9 A notable exception to this 'rule' is the inversion of the retrohydroxamate into a hydroxamate as proven by Rohmer and coworkers. 12, 14 A β-oxa analogue bearing an N-methylhydroxamate functionality showed even better DXR inhibiting properties, 15 Results hence we also envisaged the synthesis of α-fluoro hydroxamate 6.
For the introduction of the respective halogens into 2, we adopted the strategy of Iorga et al., 16 based upon the attack of a deprotonated α-monosilylated alkylphosphonate on an electrophilic halogenation reagent, in casu hexachloroethane or N-fluorobenzenesulfonimide (NFBS). 17 This straightforward onepot strategy allowed for the synthesis of both envisaged precursors 10a and 10b with just a minor modification of the desilylation conditions (vide infra) and has several advantages such as high yield, high speed, ready availability of electrophilic halogenating reagents and easy elimination of byproducts.
Unfortunately, this strategy proved to be very sensitive towards functionalities in the starting alkyl phosphonate, implying that all attempts to introduce a halogen onto a suitably protected fosmidomycin precursor using Iorga's conditions remained unsuccessful (Scheme 1).
Scheme 1. Substrates unsuccessfully tested in the halogenation reaction. First, three differently protected hydroxyamines, synthesized from diethyl 3-bromopropylphosphonate were tested. Unfortunately all reactions started to turn black after addition of the halogenation reagent, resulting in complex reaction mixtures from which the desired compounds could not or only in very low yield be isolated. Assuming that it was the protected hydroxylamine functionality that did not withstand the reaction conditions, we turned to chemically more resistant (hydroxyl)amine precursors such as a phthalimide or azide group. Here again, the halogenation conditions caused decomposition of the starting materials and were also unsuccessful when applied on TBDMS-protected 3-hydroxypropylphosphonate. These failures led us to explore a simpler phosphonate precursor, i.e.
commercially available diethyl but-3-enyl phosphonate (7) 18 , which could be halogenated in satisfying yields without noticeable breakdown to afford 10b. One side reaction observed in the synthesis of the α-chloro-derivative 10a, however, was the formation of conjugated diene 9 caused by elimination of chlorine when using the standard lithium ethoxide-ethanol deprotection for the TMS-group of intermediate 8. Hence, we decided to remove the installed TMS group by means of an acidic procedure (TBAF in acetic acid), resulting in the desired product 10 (Scheme 2).
Scheme 2. Halogenation strategy with standard desilylation conditions (EtOLi/EtOH) resulting in elimination product 9 and alternative acidic procedure (TBAF/AcOH) towards 10a. 
THF
In order to assess the influence of the introduced halogens on the ionization of these phosphonates, the pK a 's of compounds 5a and 5b as well as reference compound 2 were estimated from the pH dependence of their 31 P chemical shift. Therefore, the 31 P chemical shift of each compound was measured at different pH and plotted as a function of these pH values. The pK a of each compound is estimated to be at the pH of the inflection point of its titration curve. Of special interest here is the second pK a of each molecule, as the value of this pK a determines whether the phosphonate will be in its single-or double-ionized form at physiological pH. Therefore a cutout of the titration curves is displayed from which the pK a Figure 1 Titration curves of compounds 2, 5a and 5b around their second equivalence point 2 can be estimated (for the complete curves see Supporting Information).
From these figures, a pK a 2 of 7.35 can be estimated for reference compound 2, whereas both the α-chlorinated analogue 5a and the α-fluorinated analogue 5b show a pK a 2 of around 6. It can thus be concluded that introduction of a halogen in α-position of the phosphonate moiety indeed lowered the pK a 2 of those compounds to a pK a 2 comparable to that of a phosphate 13 The title compounds were tested in duplicate for their inhibitory effect against intraerythrocytic forms of P. falciparum (strains GHA and K1) using a microdilution assay.
and that, at a physiological pH, they will be present in their double-ionized form. 19 The results are summarized in Table 1 . All three analogues show submicromolar activity on both strains and appear to be five-to six-fold more active than the parent compound fosmidomycin and slightly superior to 2 on the K1 strain. Table 2) . Compound 3 did not show any relevant activity. On the other hand, compound 6 resulted in 85% suppression of parasitaemia at 4dpi, which dropped to 42% at 7dpi and 41% at 14dpi. The mean survival time was 11.7 days. Compound 5b resulted in 88% suppression of parasitaemia at 4dpi, which after ending the treatment also dropped to 62% at 7dpi and 32% at 14dpi.
The overall MST was 15.8 days. These data clearly demonstrate that all three synthesized compounds have promising in vitro activity and that compounds 5b and 6 surpass the antimalarial activity of (2) in vivo. In summary, three α-halogenated analogues of 2 were synthesized and surpass or equal fosmidomycin or 2 in both in vitro and in vivo antimalarial activity. These findings consolidate the assumption that electron withdrawing substituents, causing a decrease in phosphonate pK a , favor the antimalarial activity of fosmidomycin analogues. Furthermore, we provided a new example of a fosmidomycin analogue in which the (N-formyl-N-hydroxy)amino moiety, involved in a chelating interaction with a
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An important outcome of the current study is that the promising in vitro activity of the α-fluorinated analogues 5b and 6 is reflected in the P. berghei acute mouse model, while the α-aryl fosmidomycin analogue 3 failed to show significant in vivo activity despite its promising in vitro activity.
cation, can be replaced by a N-hydroxy-N-methylamide group as found in 6. This opens new perspectives to combine other favorable α-modifications with a hydroxamate moiety. 
